Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
FHTX Foghorn Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: FHTX
Price (delayed)
$4.2
Market cap
$234.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.36
Enterprise value
$206.23M
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The
Highlights
Foghorn Therapeutics's EPS has increased by 38% YoY and by 14% from the previous quarter
The company's debt fell by 19% YoY and by 6% QoQ
The equity has grown by 37% YoY but it has contracted by 35% from the previous quarter
The company's revenue fell by 31% YoY but it rose by 4% QoQ
FHTX's quick ratio is down by 22% year-on-year and by 15% since the previous quarter
Key stats
What are the main financial stats of FHTX
Market
Valuations
Earnings
Shares outstanding
55.74M
Market cap
$234.11M
Enterprise value
$206.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
11.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.77
Revenue
$23.5M
Gross profit
$23.5M
Operating income
-$97.4M
Net income
-$80.44M
EBIT
-$80.44M
EBITDA
-$71.61M
Free cash flow
-$95.86M
Per share
Balance sheet
Liquidity
EPS
-$1.36
EPS diluted
-$1.36
Free cash flow per share
-$1.53
Book value per share
-$1.11
Revenue per share
$0.37
TBVPS
$4.12
Total assets
$258.69M
Total liabilities
$320.34M
Debt
$34.85M
Equity
-$61.65M
Working capital
$154.11M
Debt to equity
-0.57
Current ratio
3.16
Quick ratio
3.12
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
-304.7%
Gross margin
100%
Net margin
-342.2%
Operating margin
-414.4%
Return on assets
-27.3%
Return on equity
N/A
Return on invested capital
-42%
Return on capital employed
-42.9%
Return on sales
-342.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FHTX stock price
How has the Foghorn Therapeutics stock price performed over time
Intraday
-3.67%
1 week
-2.33%
1 month
-0.94%
1 year
-26.06%
YTD
-11.02%
QTD
15.07%
Financial performance
How have Foghorn Therapeutics's revenue and profit performed over time
Revenue
$23.5M
Gross profit
$23.5M
Operating income
-$97.4M
Net income
-$80.44M
Gross margin
100%
Net margin
-342.2%
FHTX's operating margin is down by 37% YoY but it is up by 9% QoQ
The company's revenue fell by 31% YoY but it rose by 4% QoQ
FHTX's gross profit is down by 31% year-on-year but it is up by 4% since the previous quarter
The company's net margin fell by 25% YoY but it rose by 11% QoQ
Price vs fundamentals
How does FHTX's price correlate with its fundamentals
Growth
What is Foghorn Therapeutics's growth rate over time
Valuation
What is Foghorn Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
11.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.77
Foghorn Therapeutics's EPS has increased by 38% YoY and by 14% from the previous quarter
The equity has grown by 37% YoY but it has contracted by 35% from the previous quarter
FHTX's P/S is 94% lower than its 5-year quarterly average of 175.9 and 14% lower than its last 4 quarters average of 13.1
The company's revenue fell by 31% YoY but it rose by 4% QoQ
Efficiency
How efficient is Foghorn Therapeutics business performance
Foghorn Therapeutics's ROS has decreased by 30% YoY but it has increased by 11% from the previous quarter
The ROA has grown by 12% YoY and by 7% from the previous quarter
FHTX's return on invested capital is up by 6% since the previous quarter
Dividends
What is FHTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FHTX.
Financial health
How did Foghorn Therapeutics financials performed over time
Foghorn Therapeutics's total assets is 19% lower than its total liabilities
FHTX's quick ratio is down by 22% year-on-year and by 15% since the previous quarter
The current ratio has contracted by 22% YoY and by 15% from the previous quarter
The company's debt is 157% higher than its equity
The equity has grown by 37% YoY but it has contracted by 35% from the previous quarter
The debt to equity is up by 30% QoQ but it is down by 30% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.